Skip to content
Search
Please enter at least 3 characters.

Latest Stories

EU disease prevention agency sees risk of Covid deaths rising as Omicron subvariants spread

Two new subvariants of Omicron -- BA.4 and BA.5 -- are spreading much faster than other corovanirus variants in Europe, which could lead to more hospitalizations and deaths as they become dominant, the EU's disease prevention agency said on Monday (June 13).

Most EU countries have so far detected low rates of the two subgroups. But in countries where the proportion has risen - such as Portugal, where BA.5 accounted for 87 per cent of cases by May 30 -- there have been surges in overall cases, according to the European Centre for Disease Prevention and Control (ECDC).


The two sublineages were added to the World Health Organization's monitoring list in March and have also been designated as variants of concern by the ECDC.

Variants BA.4 and BA.5 do not appear to carry a higher risk of severe disease than other forms of Omicron. But an increase in case numbers from higher transmission rates risks leading to an increase in hospitalizations and deaths, the agency said.

"The growth advantage reported for BA.4 and BA.5 suggest that these variants will become dominant," ECDC said in a statement on its website.

Meanwhile, its US counterpart said last week BA.4 and BA.5 were estimated to make up nearly 5 per cent and 8 per cent, respectively, of coronavirus cases as of June 4.

More For You

Scottish community pharmacist working in high street pharmacy with supportive environment

The PDA wants investment to reach those who deliver services to patients every day

Pic credit: iStock

Funding boost in Scotland “needs to work for not just pharmacy owners but pharmacists too”, says PDA

An increase in funding for community pharmacies in Scotland needs to lead to a greater focus on supporting pharmacists rather than “simply sustain business models”, according to the Pharmacy Defence Association (PDA).

Earlier this week, Community Pharmacy Scotland (CPS) accepted the Scottish government’s initial financial offer for the 2025/26 fiscal year, securing a guaranteed minimum reimbursement of £120 million for community pharmacies — up from £110 million from 2024/25.

Keep ReadingShow less
Aspire Pharma acquisition boosts access to essential medicines for NHS patients in the UK

The acquisition is expected to further drive the company’s growth.

gettyimages

Aspire acquires UK distribution rights from Tetris

Aspire Pharma Limited, one of the UK’s fastest-growing specialty niche generics companies, has announced the acquisition of UK distribution rights to a number of products from Tetris Pharma, a subsidiary of Arecor Therapeutics.

These include products used in the treatment of bacterial infections—such as injectable and intravenous antibiotics—as well as a medicine indicated for acute myocardial infarction (MI) and deep vein thrombosis (DVT).

Keep ReadingShow less
GP surgery upgrades for annual appointments

The surgeries will have additional space to “see more patients, boost productivity and improve patient care”

Pic credit: iStock

GP surgery upgrades to create 8.3 million more annual appointments

Over 1,000 GP surgeries will have their premises modernised to meet the needs of a further 8.3 million appointments each year, the government has announced.

Backed by a cash injection of over £102 million, the surgeries will have additional space to “see more patients, boost productivity and improve patient care”.

Keep ReadingShow less
Wales boosts funding for pharmacy-led UTI and sore throat test services

The sore throat test (STTT) and treat service will be widely available

Pic credit: istock

Welsh pharmacies receive funding boost for clinical services

Two key clinical services will be available in 99 per cent of community pharmacies across Wales after a boost in funding.

The sore throat test (STTT) and treat service and the urinary tract infection (UTI) service have both benefitted from contractual negotiations between the Welsh Government and Community Pharmacy Wales (CPW).

Keep ReadingShow less
Paul Bennett
Paul Bennett, CEO, Royal Pharmaceutical Society
Paul Bennett, CEO, Royal Pharmaceutical Society

Pharmacists need to take advantage of independent prescribing pathways, says Bennett

Independent prescribing will be a “significant point” in the history of community pharmacy, according to Royal Pharmaceutical Society chief executive Paul Bennett.

Last month, the RPS announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

Keep ReadingShow less